FEMASYS INC. news, videos and press releases
For more news please use our advanced search feature.
FEMASYS INC. - More news...
FEMASYS INC. - More news...
- Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update
- Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations
- Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain
- Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach
- Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials
- Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
- Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
- Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
- Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
- Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed
- Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment
- Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
- Femasys to Exhibit at the Annual AAGL 2024 Global Conference
- Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
- Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed
- Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program
- Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
- Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
- Femasys Announces Infertility Clinic Customers from Coast to Coast
- Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market
- Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
- Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting
- Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
- Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution
- Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters
- Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update
- Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam
- Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe
- Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative
- Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council
